Alto Neuroscience Inc. (ANRO)
NYSE: ANRO
· Real-Time Price · USD
3.15
0.03 (0.96%)
At close: Aug 15, 2025, 3:59 PM
3.14
-0.32%
After-hours: Aug 15, 2025, 04:10 PM EDT
0.96% (1D)
| Bid | 3.08 |
| Market Cap | 85.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.18M |
| EPS (ttm) | -2.39 |
| PE Ratio (ttm) | -1.32 |
| Forward PE | -1.11 |
| Analyst | Buy |
| Ask | 3.25 |
| Volume | 57,037 |
| Avg. Volume (20D) | 236,756 |
| Open | 3.15 |
| Previous Close | 3.12 |
| Day's Range | 3.06 - 3.17 |
| 52-Week Range | 1.60 - 15.04 |
| Beta | 1.85 |
About ANRO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANRO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+25.56%
Alto Neuroscience shares are trading higher after ...
Unlock content with
Pro Subscription
9 months ago
-69.99%
Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
2 months ago · businesswire.com
Alto Neuroscience to Participate in Upcoming Investor ConferencesMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...